This page shows the latest Alzheimer's drug news and features for those working in and with pharma, biotech and healthcare.
The trial assessed TauRx’s lead investigative oral drug, HMTM, which has been tested in 598 people diagnosed with Alzheimer’s. ... He added: “Today with limited treatments for Alzheimer’s, the standard of care does not impact the underlying
Following regulatory blocks and rejections late last year, Biogen has decided to withdraw its application for its Alzheimer's drug Aduhelm (aducanumab) in Europe. ... working towards the goal of bringing new treatment options to people living with
The study used the genomes of 100, 000 people with Alzheimer’s and 600, 000 healthy individuals. ... The findings also validated the importance of amyloid beta and tau proteins, which have been under scrutiny during the drug discovery efforts in
The deal will allow AbbVie to access Syndesi’s research into Alzheimer's disease. ... AbbVie has been heavily involved in various Alzheimer’s projects, including an amyloid-beta drug the company believes could work against the degenerative disease.
monoclonal antibodies for Alzheimer's disease – will be limited exclusively to participants in qualified clinical trials. ... Following a thorough analysis, CMS discovered that although Aduhelm had the potential to help patients with Alzheimer's disease
migrate to the brain and trigger the clearance of beta amyloid plaque, one of the hallmarks of Alzheimer’s disease. ... However, there has been renewed interest across the industry in recent years, culminating in the approval of the first treatment for
More from news
Approximately 7 fully matching, plus 147 partially matching documents found.
We are expecting to see the outcomes of an FDA priority review of the potential Alzheimer’s drug, aducanumab, this year. ... Over the past two decades, Alzheimer’s drug discovery has largely focused on targeting the hallmark amyloid protein.
Tau is emerging as a target for drug development in Alzheimer’s, as well as other disorders like frontotemporal dementia. ... Organisations including the Alzheimer’s Drug Discovery Foundation (ADDF) think combinations of molecules with these
Biogen and Eisai also pulled the plug on their Alzheimer’s drug aducanumab, after advice from an independent data monitoring committee forced them to abandon the phase 3 Abeta-targeting candidate. ... It was just another in a string of late-stage
This evidence has spurred research and led. organisations including the Alzheimer’s Drug Discovery Foundation and AC Immune to conclude that combination therapies may be needed to tackle such a complex ... Read more: Brain power: fresh approaches to
Two further candidates, AL003 for Alzheimer’s disease and AL004 for multiple degenerative disorders, are also set to enter clinical trials this year. ... Diseases include Alzheimer’s, dementia with Lewy bodies, frontotemporal dementia, as well as
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
He has spent a majority of his career at Pfizer, where he held a number of senior roles including medical director for Pfizer Switzerland, European team leader for the Alzheimer's ... disease drug Aricept and medical team leader for its anti-inflammatory
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...